Peptides, honestly.

Semaglutide, Tirzepatide, BPC-157, Sermorelin, Ipamorelin, Melanotan, TB-500, PT-141. What the FDA actually approves. What telehealth legitimately prescribes. What stays research-chemical-grey. And which of these are worth your attention at 45+.

After Forty Feel Editorial · 12 min read · Updated May 2026

The peptides conversation in 2026 is a mess. On one end, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are running prime-time television ads and have FDA approval for weight loss with substantial clinical-trial evidence behind them. On the other end, a small army of online vendors sell unregulated peptides labeled for research only with shipping disclaimers and reconstitution instructions that read like a chemistry kit. In the middle is a mens-health telehealth industry that prescribes some of these legally, some of them in grey areas, and some compounded by 503A pharmacies that operate at the edge of FDA tolerance.

This article maps that landscape honestly. We name what is FDA-approved with phase-3 trial data, what is legitimately prescribed off-label by licensed clinicians, and what crosses into research-chemical territory where you are personally responsible for figuring out source quality and sterility. We do not link to any grey-market vendors. We do link to telehealth clinics with named medical directors.

Category 1: FDA-approved GLP-1 receptor agonists

Semaglutide (brand names Ozempic, Wegovy, Rybelsus) and Tirzepatide (Mounjaro, Zepbound) are the two big stories. Semaglutide is a GLP-1 agonist; tirzepatide is a dual GLP-1 / GIP agonist with somewhat better head-to-head weight loss data (SURMOUNT trials, 2022-2024).

The evidence at this point is overwhelming for adults with BMI 30+ or 27+ with weight-related comorbidity. Average weight loss in trials: 15-22% of body weight over 68 weeks for tirzepatide, 12-15% for semaglutide. Cardiovascular benefits also documented (SELECT trial, semaglutide, 2023). These are not subtle effects.

How to get them legitimately: primary care, endocrinologist, or telehealth clinic that runs proper labs and history. Hims, Henry Meds, Sequence/WW, Ro all prescribe. Insurance coverage varies wildly. Out-of-pocket cost: $500-$1,300/mo for branded; $200-$400/mo for compounded (legal under FDA 503A when in shortage, which they have been).

Category 2: Off-label peptide hormones

Several peptides that affect growth hormone secretion are prescribed off-label by anti-aging and longevity clinics. Evidence quality varies sharply.

Sermorelin — a synthetic GHRH analog. Stimulates pituitary to release growth hormone. Limited evidence in clinical trials but a long history of off-label use. Some endocrinologists prescribe for adult-onset growth hormone deficiency. Compounded, not FDA-approved for general use.

Ipamorelin / CJC-1295 — synthetic peptides that work similarly. Much weaker evidence base. Prescribed by some telehealth clinics, often paired with Sermorelin. Long-term safety data is thin.

Tesamorelin — the only FDA-approved GHRH analog (for HIV-associated lipodystrophy). Some clinicians use off-label for visceral fat in non-HIV patients. Real evidence but expensive.

Category 3: Research-chemical grey

The peptides below are sold widely online with research only labels, but are not FDA-approved for human use and are not legitimately prescribed by U.S. clinicians:

• BPC-157 — claimed healing peptide. Animal data interesting; human data essentially absent. FDA explicitly excluded from 503A compounding in 2023.
• TB-500 (Thymosin Beta-4) — similar healing claims, similar evidence gap, also FDA-restricted from compounding.
• Melanotan I and II — tanning peptides. Real effect, real risks (nausea, melanocyte changes), no clinical oversight.
• PT-141 (Bremelanotide) — actually FDA-approved as Vyleesi for womens hypoactive sexual desire disorder. Off-label use in men exists but should go through a real clinician.
• 5-amino-1MQ, MOTS-c, Epitalon — longevity-bro peptides with thin human evidence.

What we do recommend

For weight loss with strong evidence: ask your primary care about semaglutide or tirzepatide if your BMI qualifies. If insurance denies, look at Hims, Henry Meds, or Mochi for compounded options. Expect to be on it long-term — discontinuation results in significant weight regain in most patients.

For hormone optimization more broadly: get a real workup first (testosterone, free T, IGF-1, thyroid panel, fasting insulin, A1c). Most men feel better on a sleep + strength + protein floor protocol than on any peptide they could buy. The men we know who have the best outcomes on TRT or GH-axis peptides also got the basics dialed first.

For everything else: be skeptical. The midlife-male peptide industry is booming because there is real money in I want to feel 32 again at 52. Some of that money funds real research. Most of it funds compelling marketing.